Investor Relations & ESG


Our Equity Story

  1. Evotec is advancing drug discovery and development with a unique B2B model with focus on pipeline-building, offering specific solutions in the R&D continuum, as well as providing CRO/CDMO services
  2. We have built a “shared economy” in R&D with more than 500 partners working on our platform at the same time
  3. Our long-term aspiration is to develop disease-modifying therapies and potential cures; for as long as even a single disease remains untreated, the claim #researchneverstops will hold.
  4. Our mission is to discover and develop medicines that matter in efficient collaborations together with its partners, where it focuses on data-driven disease understanding, precision medicine and early disease relevance to bring probabilities of success up (“PoS up”).
  5. The combination of our capabilities and unique business model is just at the beginning to deliver strong operational growth and value creation for all our stakeholder.

Our Growth Strategy

Evotec’s growth strategy aims to cover the entirety of the early R&D value chain to impact patients’ lives by addressing a broad range of disease areas in collaboration with its partners and by utilising a modality-agnostic approach. In addition, by leveraging the value of its platforms and sharing intellectual property, Evotec seeks to de-risk its portfolio through the breadth and diversity of pipeline assets. The Company aims to have over 170 pipeline assets by the end of 2025, with its first royalties to be received in 2025.

Evotec’s team aspires to impact patient’s lives in four main areas in particular: 

PanOmics-driven drug discovery for deep disease understanding and effective therapies

IPSCs "off-the-shelf" cell therapy based on induced-pluripotent stem cells

Just – Evotec Biologics Artificial Intelligence and continuous manufacturing for better access to biologics

End-to-End Shared R&D Integrated business-to-business platform for increased probability of success from target to the clinic


Evotec’s strategic goals include:

  • Establishing Evotec’s offer as a best-in-class, integrated disease understanding and precision medicine platform
  • Strengthening Evotec’s position as the premier partner to the life sciences sector
  • Expanding the breadth of co-owned assets
  • Further innovation in biologics by Just - Evotec Biologics
  • Identifying risk-balanced, high-reward opportunities through equity investments
  • Leveraging the synergies between Evotec’s businesses

Investor Relations

The Investor Relations department of Evotec SE acts as an interface between the Company and the capital markets. Our extensive investor relations work focuses on an active, regular, comprehensive and transparent dialogue with our stakeholders, including shareholders, existing and potential investors, analysts, banks and the financial press. The various interest groups are provided with all important information about the company and have the opportunity to form a comprehensive picture of the company as well as to assess its future development in the best possible way. 


Sustainability has recently become a more and more important driver in the capital markets. Investors and analysts are increasingly including environmental, social and governance (ESG) aspects in their investment recommendations and decisions. Evotec's non-financial performance is already analysed by various rating agencies (including ecovadis, ISS, MSCI and Sustainalytics). An overview of the core ratings and the current valuation is available here

In the field of ESG, we are currently focusing on the following topics:

  • Re-Assessing our Corporate Carbon Footprint in line with the GHG Protocol in order to fulfil our commitment to set climate targets aligned with the 1.5°C goal of the Science-based Target initiative (SBTi)
  • Implementation of a data-driven and web-based ESG data tool
  • Strengthen our communication on progress with our stakeholders
  • Implementation of sustainability aspects throughout our Company with a strong focus on Diversity, Equity & Inclusion (DE&I) in particular.

Contact IR & ESG Team

Contact us

Volker Braun

SVP, Head of Global Investor Relations & ESG

T +49 40 228 999 338 vCard

Anika Meier

Investor Relations Manager

T +49 151 58358172 vCard

Anja Ben Lekhal

Investor Relations Advisor

T +49 151 51871069 vCard

Amelia Christina Gonzalez Palacios

Investor Relations & ESG Coordinator


Ambra Maria Dettmann

ESG Coordinator


Cephas Kofi Amenu

ESG Coordinator